Artelo Biosciences Investor Relations Material

Artelo Biosciences Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of proprietary therapeutics. These therapeutics are designed to modulate lipid-signaling pathways, including the endocannabinoid system, aiming to address significant unmet medical needs across various diseases and conditions such as anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Artelo is advancing a diverse portfolio of product candidates, including ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist for treating anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal targeting inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor intended for breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company is headquartered in Solana Beach, California, and its shares are listed on the Nasdaq.